Immunic (IMUX) AI Stock Analysis

• Market Cap: $86.25M
• Dividend Yield: N/A
• Average Volume (3M): 642.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.74
• Revenue Growth: N/A
• EPS Growth: 51.02%
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 95,817,535
• 10 Day Avg. Volume: 789,000
• 30 Day Avg. Volume: 642,977
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -1.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.04
• Price Target Upside: 1015.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Immunic's financial performance is the most significant factor, with consistent net losses and negative cash flow posing a substantial risk. Technical analysis suggests a bearish trend but potential for an oversold bounce. Valuation is low due to negative earnings and no dividend, indicating high risk and limited immediate return prospects.

Positive Factors

Market Position

The recent setback of a competitor therapy in RMS positions vidofludimus calcium as a potential disruptor in the oral RMS therapy market.

Therapeutic Potential

Vidofludimus calcium is differentiated by its oral, dual mode-of-action as a prospective disease modifying therapy, targeting the full spectrum of MS disease with neuroprotection and relapse prevention.

Negative Factors

Clinical Risk

The readout is not without clinical risk, given the reliance on Nurr1 activation for potential efficacy.

Financial Uncertainty

The financing outlook post-CALLIPER readout remains a key outstanding question, making clarity on the funding status important for the stock reaction.

Immunic Business Overview & Revenue Model

Company Description

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

How the Company Makes Money

Immunic makes money primarily through the development and commercialization of its drug candidates. The company focuses on advancing its pipeline through clinical trials, with the aim of achieving regulatory approval and subsequently marketing these therapies. Revenue is anticipated to be generated through direct sales, licensing agreements, and partnerships with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on sales. As a clinical-stage company, Immunic may also rely on funding from investors, grants, or other financial instruments to support its research and development activities.

Immunic Financial Statement Overview

Summary

Immunic's financials are typical of an early-stage biotech firm, with significant losses and no revenue. The balance sheet shows low leverage but declining equity, while cash flow is negative, reflecting high R&D expenditure. Recent financing boosts liquidity short-term but doesn't solve long-term cash sustainability.

Income Statement

Immunic shows consistent losses with no revenue over the years, typical for early-stage biotech companies. The TTM EBIT and EBITDA margins are substantially negative, highlighting significant operational costs relative to nonexistent revenue streams. This is a common scenario in biotech where substantial R&D investments are necessary before commercialization. Despite high net income losses, there is a trend of narrowing losses compared to previous years.

Balance Sheet

The company maintains a low debt-to-equity ratio, indicative of conservative leverage but this is overshadowed by declining equity as losses accumulate. The equity ratio remains relatively healthy, reflecting a strong asset base albeit shrinking over time. Overall, the balance sheet reflects a typical biotechnology profile with high reliance on equity financing and limited liabilities.

Cash Flow

Immunic’s cash flow demonstrates significant negative free cash flow consistent with high R&D expenditure. The operating cash flow to net income ratio remains unfavorable due to substantial cash burn. However, recent financing activities have bolstered cash reserves, offering short-term liquidity but not addressing long-term cash sustainability.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-80.00K	-111.00K	-77.00K	-85.00K	-39.00K	-50.00K
	EBIT
-95.80M	-99.22M	-119.49M	-91.67M	-48.97M	-37.03M
	EBITDA
-95.68M	-99.11M	-120.33M	-92.86M	-48.93M	-36.98M
	Net Income Common Stockholders
-96.90M	-93.61M	-154.30M	-92.79M	-43.96M	-34.83M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
38.19M	46.67M	116.37M	86.86M	127.45M	29.37M
	Total Assets
46.59M	54.30M	127.75M	139.10M	167.86M	65.95M
	Total Debt
0.00	1.33M	1.56M	584.00K	679.00K	520.00K
	Net Debt
-38.19M	-45.34M	-105.18M	-86.28M	-126.77M	-28.85M
	Total Liabilities
5.17M	25.37M	14.07M	11.98M	9.08M	7.59M
	Stockholders Equity
41.42M	28.93M	113.68M	127.11M	158.78M	58.36M
Cash Flow		Free Cash Flow
-76.26M	-71.16M	-65.26M	-83.30M	-46.27M	-28.60M
	Operating Cash Flow
-75.83M	-70.83M	-65.14M	-83.23M	-46.12M	-28.55M
	Investing Cash Flow
-426.00K	9.46M	-9.74M	-67.00K	-146.00K	10.54M
	Financing Cash Flow
74.46M	1.03M	95.76K	42.84K	144.43M	34.90M

Immunic Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMUX, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.08, and below the 200-day MA of 1.24, indicating a bearish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 42.26 is Neutral, neither overbought nor oversold. The STOCH value of 13.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMUX.

Immunic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BCRX	52 Neutral	$1.43B	―	18.68%	―	36.00%	63.50%
ARWR	50 Neutral	$1.62B	―	-600.68%	―	-98.62%	-86.21%
Sector *	48 Neutral	$6.35B	1.18	-46.25%	2.67%	19.35%	1.28%
CYTK	45 Neutral	$4.61B	―	435.49%	―	145.34%	3.20%
VKTX	42 Neutral	$2.50B	―	-17.90%	―	―	-10.27%
RDHL	41 Neutral	$3.07M	―	1155.92%	―	―	―
IMUX	36 Underperform	$86.25M	―	-424.44%	―	―	51.02%

Immunic Corporate Events

Immunic Announces $5.1 Million Securities Purchase Agreement

On April 9, 2025, Immunic, Inc. announced a securities purchase agreement with institutional and accredited investors for the issuance and sale of 5,666,667 shares of common stock, priced at $0.90 per share, generating gross proceeds of approximately $5.1 million. The offering, expected to close on April 10, 2025, aims to fund clinical trials, operations, and other corporate purposes, with Titan Partners Group acting as the sole placement agent. The net proceeds after expenses are anticipated to be around $4.6 million, impacting Immunic’s operational funding and market positioning.

Spark’s Take on IMUX Stock

According to Spark, TipRanks’ AI Analyst, IMUX is a Underperform.

Immunic’s financial performance is the most significant factor, with consistent net losses and negative cash flow posing a substantial risk. Technical analysis suggests a bearish trend but potential for an oversold bounce. Valuation is low due to negative earnings and no dividend, indicating high risk and limited immediate return prospects.

To see Spark’s full report on IMUX stock, click here.